Okun E, Johnston G P, Boniuk I, Arribas N, Escoffery R F, Grand M G
Trans Am Ophthalmol Soc. 1983;81:229-45.
Over 2500 xenon arc-treated eyes which would have qualified for inclusion in the DRS were reviewed in the format of the DRS. When comparable risk groups were compared, the results of treatment were even more favorable than reported in the DRS without the severe complications attributed to xenon treatment in the DRS. A critical analysis of the DRS gives clues for the greater amount of visual loss found with xenon than argon in the DRS. Since these complications may be avoidable in some cases and since xenon has been shown to be at least as effective as argon, it should continue to be used in the treatment of PDR.
按照糖尿病性视网膜病变研究（DRS）的格式，对超过2500只接受氙弧治疗且本可纳入DRS研究的眼睛进行了回顾。当对具有可比性的风险组进行比较时，治疗结果比DRS报告的更为有利，且没有DRS中归因于氙治疗的严重并发症。对DRS的批判性分析揭示了在DRS中氙导致的视力丧失比氩更多的线索。由于这些并发症在某些情况下可能是可以避免的，并且由于已证明氙至少与氩一样有效，因此它应继续用于增殖性糖尿病性视网膜病变（PDR）的治疗。
